All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.

Nelson, David R; Cooper, James N; Lalezari, Jacob P; Lawitz, Eric; Pockros, Paul J; Gitlin, Norman; Freilich, Bradley F; Younes, Ziad H; Harlan, William; Ghalib, Reem; Oguchi, Godson; Thuluvath, Paul J; Ortiz-Lasanta, Grisell; Rabinovitz, Mordechai; Bernstein, David; Bennett, Michael; Hawkins, Trevor; Ravendhran, Natarajan; Sheikh, Aasim M; Varunok, Peter; Kowdley, Kris V; Hennicken, Delphine; McPhee, Fiona; Rana, Khurram; Hughes, Eric A

Nelson, David R; Cooper, James N; Lalezari, Jacob P; Lawitz, Eric; Pockros, Paul J; Gitlin, Norman; Freilich, Bradley F; Younes, Ziad H; Harlan, William; Ghalib, Reem; Oguchi, Godson; Thuluvath, Paul J; Ortiz-Lasanta, Grisell; Rabinovitz, Mordechai; Bernstein, David; Bennett, Michael; Hawkins, Trevor; Ravendhran, Natarajan; Sheikh, Aasim M; Varunok, Peter; Kowdley, Kris V; Hennicken, Delphine; McPhee, Fiona; Rana, Khurram; Hughes, Eric A.

Affiliation

Nelson DR; University of Florida, Gainesville, FL.

Hepatology ; 61(4): 1127-35, 2015 Apr.

Article in En | MEDLINE | ID: mdl-25614962

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Uridine Monophosphate / Hepatitis C / Hepacivirus / Imidazoles Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Hepatology Year: 2015 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google